Page last updated: 2024-10-29

iohexol and Brugada Syndrome

iohexol has been researched along with Brugada Syndrome in 1 studies

Iohexol: An effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.
iohexol : A benzenedicarboxamide compound having N-(2,3-dihydroxypropyl)carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and an N-(2,3-dihydroxypropyl)acetamido group at the 5-position.

Brugada Syndrome: An autosomal dominant defect of cardiac conduction that is characterized by an abnormal ST-segment in leads V1-V3 on the ELECTROCARDIOGRAM resembling a right BUNDLE-BRANCH BLOCK; high risk of VENTRICULAR TACHYCARDIA; or VENTRICULAR FIBRILLATION; SYNCOPAL EPISODE; and possible sudden death. This syndrome is linked to mutations of gene encoding the cardiac SODIUM CHANNEL alpha subunit.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bowers, RW1
O'Kane, P1
Balasubramaniam, RN1

Other Studies

1 other study available for iohexol and Brugada Syndrome

ArticleYear
Type 1 Brugada ECG unmasked by intracoronary contrast media.
    Heart (British Cardiac Society), 2013, Volume: 99, Issue:2

    Topics: Brugada Syndrome; Contrast Media; Coronary Angiography; Coronary Vessels; Diagnosis, Differential; E

2013